Pharmaceuticals
Valeant close to buying 'female Viagra' maker Sprout for $1 bn
20 Aug 2015
Sprout Pharmaceuticals drug, which aims to boost a woman’s libido, yesterday received approval from the US FDA for its drug Addyi
Baxalta wants Shire to raise its $30 billion bid before talks
14 Aug 2015
Baxalta wants Shire to sweeten its $30-billion bid before it engages in talks with the Dublin-based pharmaceutical major
Roche to buy GeneWEAVE BioSciences
14 Aug 2015
India defers FTA talks with EU over GVK ban
05 Aug 2015
US FDA approves first 3D printed pill
05 Aug 2015
The US Food and Drug Administration on Monday approved the first prescription drug made through 3D printing in the US
Baxalta rejects drugmaker Shire’s approach
05 Aug 2015
India thwarts UK firm’s bid to patent compound of turmeric, pine bark and tea for treating hair loss
03 Aug 2015
Dr Reddy's Q1 net up 14% at Rs626 crore
30 Jul 2015
Firms “underinvest” in long-term cancer research: study
28 Jul 2015
Pharmaceutical firms “underinvest” in long-term research to develop new cancer-fighting drugs due to the greater time and cost required to conduct such research
Teva in $40.5-bn pact to buy Allergan's generics, ends Mylan bid
27 Jul 2015
Post-merger, Allergan will have one of the broadest product portfolios and strongest pipelines in the generics industry
Teva in talks to buy Allergan's generic-drug unit for $45 bn: report
27 Jul 2015
A deal with Allergan would indicate that Teva could be considering abandoning its plan to buy Mylan NV after the Netherlands-based company rejected its $40-billion takeover offer
Lupin buys US generics drug maker Gavis for $880 mn
23 Jul 2015
The cash-free and debt-free acquisition creates the fifth-largest portfolio of new drug filings with the US FDA, addressing a $63.8-billion market
Thoratec Corp accepts US heart device maker St Jude Medical's $3.4-bn offer
22 Jul 2015
The deal will accelerate St. Jude Medical’s growth strategy by adding Thoratec’s complementary products and technologies to its own portfolio of heart failure products
Horizon Pharma raises offer to buy Depomed to $33 per share
22 Jul 2015
Irish biopharmaceutical company Horizon Pharma Plc yesterday raised its offer to buy smaller US rival Depomed Inc to $33 per share in abid to nearly double its drugs portfolio
Valeant to buy Egyptian drugmaker Amoun for $800 mn
18 Jul 2015
Founded in 1998, Amoun is the largest pharmaceutical company in Egypt and expects to reach valuation of Egyptian £1.75 billion this year, with annual growth of approximately 20 per cent
Celgene to buy drugmaker Receptos for $7.2 bn
15 Jul 2015
Featured articles
Lighter than air, yet very, very powerful
By Kiron Kasbekar | 03 Jan 2024
In March 2013 Chinese scientists pulled off a remarkable feat. They created the world’s lightest aerogel. Tipping the scales at a mere 0.16 milligrams per cubic centimeter – that’s a sixth of the weight of air!
COP28 explained: A closer look at COP28's climate change solutions
By Aniket Gupta | 27 Dec 2023
The 28th United Nations Climate Change Conference, also known as COP28, took place from 30th November 2023, to 13th December 2023, at Expo City in Dubai, United Arab Emirates.
What is a Ponzi scheme?
By Aniket Gupta | 06 Dec 2023
Ponzi schemes have long captivated the public imagination, drawing unsuspecting investors into a web of illusion and deception.
The Rise and Rise of HDFC Bank
03 Jul 2023
HDFC, which surged ahead of global majors like HSBC Holdings Plc and Citigroup Inc and left Indian peers like State Bank of India and ICICI Bank in market capitalisation, now ranks fourth largest among the world’s most valuable banks, after JPMorgan Chase & Co, Industrial and Commercial Bank of China Ltd and Bank of America Corp
India’s Millet Revolution To Enrich Global Food Basket
02 Apr 2023
Millets, a healthier and cheaper substitute to wheat and rice, are indigenous to many parts of the world, especially in the semiarid tropics of Asia and Africa, and offers a big scope for expanding production and consumption in the foodgrain deficient African continent
Market predator Hindenburg preys on Adani stock
06 Mar 2023
Almost a month after the damning report of short-seller Hindenburg Research on the Adani Group that claimed that the seven stocks within the group were about 85 per cent overvalued, one of the group's stocks, Adani Total Gas, closed at Rs835 on the BSE, down nearly 79 per cent from its 24 January level, almost close to reaching that valuation
.jpg "CBDT explains Budget proposal on capital gains tax")
.jpg "Economic Survey projects India’s GDP growth at 6.5–7% in 2024-25")
.jpg "Adani-Sirus joint venture to acquire 77.5% stake in Coredge.io parent Parserlabs")
